Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombination activating genes (RAG) in lymphoma development.

Brian B Haines1, Chun Jeih Ryu, Jianzhu Chen

  • 1Center for Cancer Research, Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA. bhaines@mit.edu

Cell Cycle (Georgetown, Tex.)
|May 12, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Anti-Tumor Immunity and Immunotherapy Efficacy.

Cancer research·2026
Same author

Fouling-Free Inertial Microfluidic Cell Clarification for Lentivirus Manufacturing.

Biotechnology and bioengineering·2026
Same author

Temporal control of sgRNA library activation unlocks large-scale in vivo CRISPR screens.

Cell reports methods·2026
Same author

High-recovery AAV clarification using a multiplexed spiral inertial microfluidic platform.

Lab on a chip·2026
Same author

Identification of a Rejection Signature and Distinct Inflammatory Alveolar Macrophage Populations Post-lung Transplantation.

Transplantation·2026
Same author

Intensified lentiviral vector perfusion bioprocessing with a spiral inertial microfluidic cell retention device.

Lab on a chip·2026

Recombination activating genes (RAG) are crucial for immune diversity but can cause lymphoma when misregulated. Impaired lymphocyte development during RAG expression may promote cancer, as shown in a novel mouse model.

Area of Science:

  • Immunology
  • Molecular Biology
  • Oncology

Background:

  • Recombination activating genes (RAG) mediate DNA recombination for immune repertoire diversity in lymphocytes.
  • Aberrant RAG activity is linked to various human and mouse lymphomas through mechanisms like gene deregulation and oncogene formation.

Purpose of the Study:

  • To establish and utilize a T cell receptor enhancer (Ebeta) deficient mouse model to investigate RAG activity in lymphoma development.
  • To explore the hypothesis that impaired early lymphocyte development during RAG expression is a pro-carcinogenic event.

Main Methods:

  • Development of a T cell receptor enhancer (Ebeta) deficient mouse model.
  • In vivo studies to observe lymphoma development in the context of RAG activity.
  • Comparative analysis with existing model systems.

Related Experiment Videos

Main Results:

  • The Ebeta-deficient mouse serves as a tractable in vivo model for studying RAG's role in lymphoma.
  • Demonstrated the potential for impaired lymphocyte development during RAG expression to initiate carcinogenesis.

Conclusions:

  • RAG activity, while essential for immunity, can drive lymphomagenesis when dysregulated.
  • Early lymphocyte development defects during RAG expression are potentially pro-carcinogenic.
  • The developed mouse model facilitates assessment of RAG's role in human lymphoid malignancies.